Key bottlenecks in M/XDR-TB control and patient care
Maximizing research opportunities to address M/XDR-TB
Against the backdrop of static research funding for TB, this paper calls for greater involvement of all governments, especially those of the emerging economies, and funding agencies in research on MDR-TB. Multi-agency and country coordination is recommended to develop new rapid methods for detection of M/XDR-TB and field test them. Similarly, new medicines are urgently needed, as well as the design and funding of randomized controlled trials for treatment and prevention of MDR-TB using both new and available compounds. In addition, opportunities are clearly being missed, to make full use of the funds available for operational research within existing Global Fund grants. One essential area where such funds could be used is in investigating the causes of drug resistance in different settings.